Paul Blanchfield
President at LANTHEUS HOLDINGS, INC.
Net worth: 6 M $ as of 31/03/2024
Profile
Paul Blanchfield is currently the President at Lantheus Holdings, Inc. He previously worked as the General Manager-Nordic Baltics at Shire Plc and as the Head-US Immunology Business Unit at Takeda Pharmaceutical Co., Ltd.
Mr. Blanchfield completed his undergraduate degree at Duke University and holds graduate degrees, including an MBA, from Stanford University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
LANTHEUS HOLDINGS INC
0.15% | 17/04/2024 | 102,677 ( 0.15% ) | 6 M $ | 31/03/2024 |
Paul Blanchfield active positions
Companies | Position | Start |
---|---|---|
LANTHEUS HOLDINGS, INC. | President | 20/03/2023 |
Former positions of Paul Blanchfield
Companies | Position | End |
---|---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | - |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
Training of Paul Blanchfield
Duke University | Undergraduate Degree |
Stanford University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
LANTHEUS HOLDINGS, INC. | Health Technology |
Private companies | 1 |
---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Stock Market
- Insiders
- Paul Blanchfield